Akagera Medicines key facts
as of Oct 2026- Developer of novel liposomal formulations of antibacterial drugs intended to treat tuberculosis.
- Akagera Medicines is valued at approximately $345.0M as of Oct 2026 (last reported valuation).
- It has raised $62.2M; the latest was Later Stage VC ($30.0M) in Jan 2025.
- Notable investors include Coalition for Epidemic Preparedness Innovations, Crocker Ventures.
- Status: Privately Held (backing).
Akagera Medicines's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·Watch Akagera Medicines: the Monday email on marks, rounds and moves
Akagera Medicines funding rounds
No funding rounds for Akagera Medicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Akagera Medicines
2Akagera Medicines valuation
Akagera Medicines's last reported valuation was $345 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Akagera Medicines investors
2 investors are on record for Akagera Medicines, including Coalition for Epidemic Preparedness Innovations and Crocker Ventures.
About Akagera Medicines
Developer of novel liposomal formulations of antibacterial drugs intended to treat tuberculosis. The company develops novel liposomal formulations of antibacterial drugs to treat tuberculosis and other infectious diseases in macrophages responsible for phagocytosis, enabling patients to get the treatment for tuberculosis, eliminating toxicity, and lowering the costs to patients and society.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2018
- Employees
- 16
- Website
- akageramedicines.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.